- Home
- CBNA vs IPHA Comparison
CBNA vs IPHA Comparison
Compare CBNA & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBNA
- IPHA
- Stock Information
- Founded
- CBNA 2006
- IPHA 1999
- Country
- CBNA United States
- IPHA France
- Employees
- CBNA N/A
- IPHA N/A
- Industry
- CBNA
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- CBNA
- IPHA Health Care
- Exchange
- CBNA NYSE
- IPHA Nasdaq
- Market Cap
- CBNA 159.8M
- IPHA 160.1M
- IPO Year
- CBNA 2024
- IPHA 2019
- Fundamental
- Price
- CBNA $25.94
- IPHA $2.44
- Analyst Decision
- CBNA Buy
- IPHA Strong Buy
- Analyst Count
- CBNA 3
- IPHA 1
- Target Price
- CBNA $29.67
- IPHA $11.00
- AVG Volume (30 Days)
- CBNA 12.6K
- IPHA 33.6K
- Earning Date
- CBNA 04-28-2025
- IPHA 03-27-2025
- Dividend Yield
- CBNA N/A
- IPHA N/A
- EPS Growth
- CBNA 59.84
- IPHA N/A
- EPS
- CBNA 4.10
- IPHA N/A
- Revenue
- CBNA $57,087,000.00
- IPHA $20,831,349.00
- Revenue This Year
- CBNA N/A
- IPHA $209.83
- Revenue Next Year
- CBNA $22.92
- IPHA $83.96
- P/E Ratio
- CBNA $6.34
- IPHA N/A
- Revenue Growth
- CBNA 62.88
- IPHA N/A
- 52 Week Low
- CBNA $20.01
- IPHA $1.29
- 52 Week High
- CBNA $27.56
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- CBNA N/A
- IPHA 73.73
- Support Level
- CBNA N/A
- IPHA $2.22
- Resistance Level
- CBNA N/A
- IPHA $2.34
- Average True Range (ATR)
- CBNA 0.00
- IPHA 0.15
- MACD
- CBNA 0.00
- IPHA 0.04
- Stochastic Oscillator
- CBNA 0.00
- IPHA 84.40
About CBNA CHAIN BRIDGE BANCORP INC
Chain Bridge Bancorp Inc is engaged in banking industry. It offers commercial and personal banking services, including deposits, treasury management, payments, loans, commercial lending, residential mortgage financing, consumer loans, trusts and estate administration, wealth management, and asset custody.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.